Neoleukin Therapeutics Inc NGNE Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$25.31 down $0.34, 1.33% at close Nov 6
Last close · Previous close $25.65
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$5.04Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$25.31down $0.34, 1.33%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$25.65Nov 5
- Volume324.88KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume354.21KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $15.93 to $43.66; now $25.31
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
NGNE beat the S&P 500 in 3 of 7 periods.
| Period | NGNE and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NGNE: down 0.6% S&P 500: down 5.6% | NGNE beat the S&P 500 by 5.0 percentage points Beat |
| 3M | NGNE: down 28.9% S&P 500: down 4.1% | NGNE trailed the S&P 500 by 24.8 percentage points Trailed |
| YTD | NGNE: up 22.9% S&P 500: up 8.7% | NGNE beat the S&P 500 by 14.2 percentage points Beat |
| 1Y | NGNE: down 5.1% S&P 500: up 10.9% | NGNE trailed the S&P 500 by 16.0 percentage points Trailed |
| Long term | ||
| 3Y | NGNE: up 85.0% S&P 500: up 75.0% +22.8% vs +20.5% a year | NGNE beat the S&P 500 by 10.0 percentage points Beat |
| 5Y | NGNE: down 83.5% S&P 500: up 67.8% −30.3% vs +10.9% a year | NGNE trailed the S&P 500 by 151.3 percentage points Trailed |
| 10Y | NGNE: down 87.8% S&P 500: up 313.1% −18.9% vs +15.2% a year | NGNE trailed the S&P 500 by 400.9 percentage points Trailed |
$10,000 invested in NGNE 10 years ago (Nov 4, 2016) would be worth about $1,224 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
NGNE beat the S&P 500 in 3 of 7 periods.
| Period | NGNE and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NGNE: down 0.6% S&P 500: down 5.6% | NGNE beat the S&P 500 by 5.0 percentage points Beat |
| 3M | NGNE: down 28.9% S&P 500: down 4.3% | NGNE trailed the S&P 500 by 24.6 percentage points Trailed |
| YTD | NGNE: up 22.9% S&P 500: up 7.8% | NGNE beat the S&P 500 by 15.1 percentage points Beat |
| 1Y | NGNE: down 5.1% S&P 500: up 9.7% | NGNE trailed the S&P 500 by 14.8 percentage points Trailed |
| Long term | ||
| 3Y | NGNE: up 85.0% S&P 500: up 68.8% +22.8% vs +19.1% a year | NGNE beat the S&P 500 by 16.2 percentage points Beat |
| 5Y | NGNE: down 83.5% S&P 500: up 56.9% −30.3% vs +9.4% a year | NGNE trailed the S&P 500 by 140.4 percentage points Trailed |
| 10Y | NGNE: down 87.8% S&P 500: up 252.6% −18.9% vs +13.4% a year | NGNE trailed the S&P 500 by 340.4 percentage points Trailed |
$10,000 invested in NGNE 10 years ago (Nov 4, 2016) would be worth about $1,224 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$442.60
Closing high on . Now 94.3% below that record.
Split-adjusted daily closes since Mar 7, 2014.
Stock splits
2
Latest: 1-for-4 on . Share counts adjust after each split.
Both splits
- 1-for-4
- 1-for-5
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$111.11M
- Diluted EPS
- −$5.04
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$20.22M | −$1.19 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$19.51M | −$0.99 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$22.65M | −$1.08 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$22.02M | −$1.05 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$20.95M | −$0.99 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$24.74M | −$1.13 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$30.93M | −$1.39 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$34.49M | −$1.53 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$60.69M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$55.19M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$36.32M | −$117.28 |
| FY24 (Dec 31, 2024) | $0.00 | −$75.14M | −$4.28 |
| FY25 (Dec 31, 2025) | $0.00 | −$90.35M | −$4.24 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$87.71MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$86.82MLast 12 months
- Capital spending$890.00KLast 12 months
Shareholder returns
- $36.85MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $225.73MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$8.35MAs of Jun 30, 2026
- Net cash$217.39MAs of Jun 30, 2026
- 10.64As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.04As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −45.1%Last 12 months
Over the last 12 months, Neoleukin Therapeutics lost money: its net loss was 45.1% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −41.0%Last 12 months
Over the last 12 months, Neoleukin Therapeutics’s net loss was 41.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Neoleukin Therapeutics Inc
Neoleukin is a biopharmaceutical company that has historically created next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin developed sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. As of March 2023, the Company has restructured its operations to conserve capital.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Washington, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
NGNE news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
NGNE stock FAQ
What is NGNE stock’s price today?
Neoleukin Therapeutics (NGNE) traded at $25.31 at the close on , down $0.34 (1.33%) from the previous close of $25.65. Over the past 52 weeks it has traded between $15.93 and $43.66.
If you invested $1,000 in NGNE 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in NGNE on would be worth about $122 at the close on , a total return of −87.8%. The same $1,000 would be worth $165 if invested five years ago and $949 if invested one year ago. Past performance doesn’t predict future returns.
What is NGNE’s P/E ratio?
NGNE’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$5.04).
What are NGNE’s earnings per share?
NGNE’s diluted earnings per share were −$5.04 over the four quarters to , compared with −$4.31 in the twelve months before. The latest quarter (Q2 FY26) brought −$1.53 per share, against −$1.05 a year earlier (how EPS works).
Does NGNE pay a dividend?
Neoleukin Therapeutics hasn’t paid a dividend in the last twelve months.
What is NGNE’s 52-week high and low?
Over the past 52 weeks NGNE has traded as low as $15.93 and as high as $43.66. At $25.31 at the close on , it is 42.0% below that high and 58.9% above the low.
What is NGNE’s all-time high?
NGNE’s highest closing price was $442.60 on , adjusted for stock splits. At $25.31 at the close on , it is 94.3% below that record.
Has NGNE stock ever split?
Yes, twice: 1-for-5 on ; 1-for-4 on .
How has NGNE stock performed?
Including dividends and measured to the close on , NGNE has returned +22.9% so far this year and −5.1% over the past year, and −83.5% over five years (−30.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Neoleukin Therapeutics in?
Neoleukin Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Washington, USA.
What exchange does NGNE trade on?
Neoleukin Therapeutics trades on the Nasdaq under the ticker symbol NGNE. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.